Expression of Glucose Transporter-1 (Glut-1) in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma
DOI:
https://doi.org/10.52783/jns.v14.2160Keywords:
Oral Epithelial Dysplasia, Oral Squamous Cell Carcinoma, Glucose Transporter-1, ImmunohistochemistryAbstract
Aim of the study: Expression of Glucose Transporter-1 (GLUT-1) in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma.
Material & methods: A total of 50 cases formed the study, which were divided into two main groups; Group I - Oral Epithelial Dysplasia (n=30) and Group II - Oral Squamous Cell Carcinoma (n=20).
Results: The results were tabulated using Chi-square test and Fischer’s exact test for comparison of GLUT-1 expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma. GLUT-1 has a consistent role in oral premalignant and malignant lesions and that its expression level and activity appear to be associated with malignant transformation and aggressiveness.
Conclusion: The expression of GLUT-1 increased with disease severity; OSCC showed the highest intensity, followed by OED and NOM.
Downloads
Metrics
References
Voet D, Voet J, Pratt W in Fundamentals of biochemistry life at the molecular level 2nd edition, Asia, John Wiley & Sons, 2006 (184-185)
Pereira KMA, Feitosa SG, Lima ATT, Luna ECM, Cavalcante RB, Lima KCD et al. Immunohistochemical evaluation of glucose transporter type 1 in epithelial dysplasias and oral squamous cell carcinoma. 2016;17(1):147-151
Younes M, Lechago V, Somoano R, Mosharaf M and Lechago J .Wide expression of the human erythrocytes glucose transport GLUT1 in human cancers.1996;56:1164-1167
Reisser C, Eichhorn K, Mende HC, Born AI and Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinoma of the head and neck .1998;80:194-198
Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Weiand S et al . Overexpression of GLUT-1 and increased glucose metabolism in tumors are associated with poor prognosis in patients with oral squamous cell carcinoma. 2003;97(4):1015-1024
Varshitha A. Prevalence of oral cancer in India. Pharm. Sci & Res, 2015;7(10):845-848.
Angadi VC, Angadi PV. GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma and verrucous carcinoma 2015; 57(2):115-122
Li CX, Sun JL, Gong ZC, Lin ZQ and Liu H. Prognostic value of GLUT-1 expression in oral squamous cell carcinoma.2016;95(45):1-7
Rao SR, Sundaram S, Lavu V. Immunolocalization of glucose transporter 4 in human gingival. 2012;23(5):565-567
Stanirowski et al. Impact of pre-gestational and gestational diabetes mellitus on the expression of glucose transporters GLUT-1, GLUT-4 and GLUT-9 in human term placenta. 2017; 55:799–808
Ruddlowski et al .GLUT1 Messenger RNA and Protein Induction Relates to the Malignant Transformation of Cervical Cancer. Am J Clin Pathol2003;120:691- 698.
Carvalho et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. CLINICS. 2011;66(6):965-97
Choi YS et al. Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue. Cancer Res Treat. 2007;39(3):109-115
Harshani MJ, Yeluri S, Guttikonda VR. Glut-1 as a prognostic biomarker in oral squamous cell carcinoma. Jomfp. 2014;18(3):272-278
Wang XX et al. Hypoxia-inducible factor-1α and glucose transporter 1 in the malignant transformation of oral lichen planus. Int J Clin Exp Pathol. 2017;10(8):8369-8376
Kato Y et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod pathol. 2007; 20:215–220
Kurokawa T et al. Expression of glut-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [f-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int. J. Cancer. 2004; 109:926–932
Leino RL, Gerhart DZ, Bueren AM, Mccall AL, Drewes LR. Ultrastructural Localization of GLUT 1 and GLUT 3 Glucose Transporters in Rat Brain. Journal of Neuroscience Research. 1997; 49:617–626
Wang et al. Correlation of GLUT1 and GLUT-3 expression with F-18 FDG uptake in pulmonary inflammatory lesion. JMed. 2016:95- 48
Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations. Am J Surg Pathol 2013;37:421–426
Ayala FRR. Glut1 and Glut3 as Potential Prognostic Markers for Oral Squamous Cell Carcinoma. JMpdi. 2010; 15:2374-2387
Paula E, Waner P, Mizeracki A, Martin C. GLUT I: A Newly Discovered Immunohistochemical Marker for Juvenile Hemangiomas. Jomfp. 2001;31(1):11-22
Fujino M et al. Expression of glucose transporter-1 is correlated with hypoxia- inducible factor 1α and malignant potential in pancreatic neuroendocrine tumors. Joncol. 2016;12: 3337-3343
Muratori L et al. HERG1 positivity and Glut-1 negativity identifies high-risk TnM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. OncoTargets and Therapy 2016;9 :6325–6332
Kalir et al. Immunohistochemical Staining of GLUT1 in Benign, Borderline, and Malignant Ovarian Epithelia. J American Cancer. 2002;94(4):1078-1082.
Eckert AW, Lautner MHW, Taubert H, Schubert J, Bilkenroth U. Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients. 2008; 20:1381-1385.
Starska K et al. Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer—the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis. Tumor Biol. 2015; 36:2309–2321.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
